Ultragenyx Stock Pre-Market (-42%) : Phase 3 Setrusumab Trials Fail Primary Endpoint

December 30th, 2025 by Trefis Team
RARE: Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical

Ultragenyx (RARE) is collapsing in the pre-market, down -42% after announcing its Phase 3 Orbit and Cosmic studies for Setrusumab in Osteogenesis Imperfecta (OI) failed to meet their primary endpoints. This is a significant blow to a key pipeline asset. Can the stock find any footing after such a catastrophic failure?

The sell-off is a direct result of late-stage clinical trial failure. Setrusumab, a key drug in development for a rare bone disease, did not show a statistically significant reduction in fracture rates.

  • This is a structural setback, not just noise. It removes a major potential revenue driver from the company’s future.
  • While a secondary endpoint of improving bone mineral density was met, this is unlikely to be sufficient for FDA approval.
  • The company has announced it will implement ‘significant expense reductions’, signaling the financial impact of this failure.
But here is the interesting part. You are reading about this -42% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to reduce exposure to losers.

Relevant Articles
  1. The Path to 10x (Part II): Innodata’s Core Engines
  2. After a 50% Drop, Is ServiceNow Stock Worth Buying?
  3. How To Buy Chewy Stock At $15
  4. PLTR Stock: The Math Hidden In Its Price
  5. Under The Hood: The Real Range Wall Street Is Pricing For CIEN
  6. MU Stock: History Signals A Rebound After 13% Drop

Playbook On Market Open

Given the drastic -42% pre-market decline, expect significant volatility at the open. The market will likely test the pre-market lows immediately. A crucial psychological battle will ensue around the $20.00 pivot, determining if short covering or continued liquidation prevails. Sentiment is overwhelmingly negative, setting up a potential Gap & Fade scenario.

  • $20.00 is a critical pivot; reclaiming it might draw bottom-fishers.
  • Failure to hold pre-market lows would signal further downside acceleration.
  • Analyst downgrades expected to increase selling pressure and volatility.

Verdict

FADE THE GAP: The deep pre-market discount and fundamental setback suggest sustained selling pressure. Expect a strong push to test and likely break below the $20.00 pivot within the first 30 minutes, leading to further declines.
Understanding price behavior can give you and edge. See more.

Want to make sure you never miss the explainer on RARE’s next move? Stay updated with Upcoming Events and Latest Analyses

That’s for now, but so much more goes into evaluating a stock from long-term investment perspective. We make it easy with our Investment Highlights

The Best Investors Think In Portfolios

Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.